| scholarly article | Q13442814 |
| P50 | author | Stephen W. Fesik | Q86531385 |
| P2093 | author name string | Qi Sun | |
| Edward T Olejniczak | |||
| Alex G Waterson | |||
| Jason Phan | |||
| Michael C Burns | |||
| Olivia W Rossanese | |||
| Taekyu Lee | |||
| J Phillip Kennedy | |||
| R Nathan Daniels | |||
| DeMarco Camper | |||
| P2860 | cites work | Structural evidence for feedback activation by Ras.GTP of the Ras-specific nucleotide exchange factor SOS | Q24297384 |
| Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF | Q24298749 | ||
| Structural analysis of autoinhibition in the Ras activator Son of sevenless | Q24309253 | ||
| The structural basis of the activation of Ras by Sos | Q24320225 | ||
| Crystal structure of ARF1*Sec7 complexed with Brefeldin A and its implications for the guanine nucleotide exchange mechanism | Q27642843 | ||
| RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth | Q27659493 | ||
| Stabilizing a weak binding state for effectors in the human ras protein by cyclen complexes | Q27660611 | ||
| In silico discovery of small-molecule Ras inhibitors that display antitumor activity by blocking the Ras-effector interaction | Q27677868 | ||
| Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity | Q27678097 | ||
| Discovery of Small Molecules that Bind to K-Ras and Inhibit Sos-Mediated Activation | Q27678948 | ||
| K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions | Q27680654 | ||
| Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy? | Q27690752 | ||
| RAS oncogenes: weaving a tumorigenic web | Q28250360 | ||
| A Ras-induced conformational switch in the Ras activator Son of sevenless | Q28914749 | ||
| ras oncogenes in human cancer: a review | Q29547769 | ||
| RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF | Q29616828 | ||
| Essential role for oncogenic Ras in tumour maintenance | Q30150290 | ||
| A comprehensive survey of Ras mutations in cancer | Q30416821 | ||
| Activation of multiple signaling pathways causes developmental defects in mice with a Noonan syndrome–associated Sos1 mutation | Q34360215 | ||
| Oncogene cooperation in tumor maintenance and tumor recurrence in mouse mammary tumors induced by Myc and mutant Kras | Q34763792 | ||
| SOS1 mutations in Noonan syndrome: molecular spectrum, structural insights on pathogenic effects, and genotype-phenotype correlations | Q35056507 | ||
| NMR-based functional profiling of RASopathies and oncogenic RAS mutations. | Q36712670 | ||
| Membrane-dependent signal integration by the Ras activator Son of sevenless | Q36737651 | ||
| Sos-mediated cross-activation of wild-type Ras by oncogenic Ras is essential for tumorigenesis | Q36808753 | ||
| Post-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets | Q36856455 | ||
| Andrographolide derivatives inhibit guanine nucleotide exchange and abrogate oncogenic Ras function | Q36950248 | ||
| Ras inhibition via direct Ras binding--is there a path forward? | Q38035669 | ||
| Oncogenic and wild-type Ras play divergent roles in the regulation of mitogen-activated protein kinase signaling | Q39252593 | ||
| Specificity and mechanism of action of EHT 1864, a novel small molecule inhibitor of Rac family small GTPases. | Q40068834 | ||
| Sulindac-derived Ras pathway inhibitors target the Ras-Raf interaction and downstream effectors in the Ras pathway | Q40597101 | ||
| Structure-based mutagenesis reveals distinct functions for Ras switch 1 and switch 2 in Sos-catalyzed guanine nucleotide exchange | Q43595428 | ||
| Analysis of intrinsic and CDC25-stimulated guanine nucleotide exchange of p21ras-nucleotide complexes by fluorescence measurements | Q70793466 | ||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 3401-6 | |
| P577 | publication date | 2014-03-04 | |
| P1433 | published in | Proceedings of the National Academy of Sciences of the United States of America | Q1146531 |
| P1476 | title | Approach for targeting Ras with small molecules that activate SOS-mediated nucleotide exchange | |
| P478 | volume | 111 |
| Q35689539 | A Homogenous Bioluminescent System for Measuring GTPase, GTPase Activating Protein, and Guanine Nucleotide Exchange Factor Activities |
| Q40125605 | A Role for Mitochondrial Translation in Promotion of Viability in K-Ras Mutant Cells |
| Q55384170 | Activation of Rho Family GTPases by Small Molecules. |
| Q97532176 | Altering the response to radiation: radiosensitizers and targeted therapies in pancreatic ductal adenocarcinoma: preclinical and emerging clinical evidence |
| Q42332071 | Arresting kinase suppressor of Ras in an inactive state |
| Q55618585 | BRET-based RAS biosensors that show a novel small molecule is an inhibitor of RAS-effector protein-protein interactions. |
| Q40989800 | Combined Inhibition of Cyclin-Dependent Kinases (Dinaciclib) and AKT (MK-2206) Blocks Pancreatic Tumor Growth and Metastases in Patient-Derived Xenograft Models. |
| Q35590750 | Combined rational design and a high throughput screening platform for identifying chemical inhibitors of a Ras-activating enzyme |
| Q48031809 | Crystal Structure of a Human K-Ras G12D Mutant in Complex with GDP and the Cyclic Inhibitory Peptide KRpep-2d. |
| Q43490714 | Dimerization opens new avenues into Ras signaling research |
| Q38608107 | Direct Modulation of Small GTPase Activity and Function |
| Q35089991 | Direct inhibition of oncogenic KRAS by hydrocarbon-stapled SOS1 helices |
| Q38911598 | Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design |
| Q64233821 | Discovery of High-Affinity Noncovalent Allosteric KRAS Inhibitors That Disrupt Effector Binding |
| Q57773818 | Discovery of Inhibitors of Protein-Protein Interactions Using Fragment-Based Methods |
| Q91789068 | Discovery of Quinazolines That Activate SOS1-Mediated Nucleotide Exchange on RAS |
| Q61809925 | Discovery of potent SOS1 inhibitors that block RAS activation via disruption of the RAS-SOS1 interaction |
| Q60933000 | Disruption of the Interaction of RAS with PI 3-Kinase Induces Regression of EGFR-Mutant-Driven Lung Cancer |
| Q38891257 | Drugging Ras GTPase: a comprehensive mechanistic and signaling structural view |
| Q35163434 | Drugging the undruggable RAS: Mission possible? |
| Q39604170 | Dynamic studies of H-Ras•GTPγS interactions with nucleotide exchange factor Sos reveal a transient ternary complex formation in solution. |
| Q46715840 | Expanding the Scope of Electrophiles Capable of Targeting K-Ras Oncogenes. |
| Q90357653 | From basic researches to new achievements in therapeutic strategies of KRAS-driven cancers |
| Q26820880 | Genomically driven precision medicine to improve outcomes in anaplastic thyroid cancer |
| Q49997158 | High-throughput screening identifies small molecules that bind to the RAS:SOS:RAS complex and perturb RAS signaling |
| Q47155582 | Identification of a New Potent Inhibitor Targeting KRAS in Non-small Cell Lung Cancer Cells |
| Q52677215 | Impairment of K-Ras signaling networks and increased efficacy of epidermal growth factor receptor inhibitors by a novel synthetic miR-143. |
| Q27684047 | In situ selectivity profiling and crystal structure of SML-8-73-1, an active site inhibitor of oncogenic K-Ras G12C |
| Q37540897 | Inhibition of RAS function through targeting an allosteric regulatory site. |
| Q38548325 | KRAS Engages AGO2 to Enhance Cellular Transformation |
| Q26751520 | KRAS Mutant Pancreatic Cancer: No Lone Path to an Effective Treatment |
| Q36883272 | Lead identification for the K-Ras protein: virtual screening and combinatorial fragment-based approaches |
| Q40325189 | Monitoring Ras Interactions with the Nucleotide Exchange Factor Son of Sevenless (Sos) Using Site-specific NMR Reporter Signals and Intrinsic Fluorescence |
| Q36290367 | Multivalent Small-Molecule Pan-RAS Inhibitors. |
| Q35824701 | Protein-protein interactions as drug targets |
| Q39407402 | RAS Proteins and Their Regulators in Human Disease |
| Q96302844 | RAS-targeted therapies: is the undruggable drugged? |
| Q57466084 | Raman micro-spectroscopy monitors acquired resistance to targeted cancer therapy at the cellular level |
| Q46107918 | Ras Binder Induces a Modified Switch-II Pocket in GTP and GDP States |
| Q27318713 | Rational design of small molecule inhibitors targeting the Ras GEF, SOS1. |
| Q48246978 | Recent advances in the biology and therapy of medullary thyroid carcinoma. |
| Q92534142 | Second harmonic generation detection of Ras conformational changes and discovery of a small molecule binder |
| Q35655881 | Site-specific processing of Ras and Rap1 Switch I by a MARTX toxin effector domain |
| Q58046152 | Small molecule inhibitors of RAS-effector protein interactions derived using an intracellular antibody fragment |
| Q35188280 | Small-molecule modulation of Ras signaling |
| Q61809912 | Structure-based development of new RAS-effector inhibitors from a combination of active and inactive RAS-binding compounds |
| Q30367145 | Structure-based inhibition of protein-protein interactions. |
| Q38272894 | Targeting RAS-ERK signalling in cancer: promises and challenges |
| Q48151533 | Targeting the α4-α5 interface of RAS results in multiple levels of inhibition. |
| Q52722195 | The Interdependent Activation of Son-of-Sevenless and Ras. |
| Q36669604 | The disordered hypervariable region and the folded catalytic domain of oncogenic K-Ras4B partner in phospholipid binding |
| Q57060145 | Therapeutic strategies to target RAS-mutant cancers |
| Q53081170 | Variable phenotypic expression in a large Noonan syndrome family segregating a novel SOS1 mutation. |
| Q107514636 | GTPase HRAS - Son of sevenless homolog 1 complex | described by source | P1343 |
Search more.